HemaCare Corp (OTCMKTS:HEMA) is a biotechnology company specializing in the procurement and preparation of primary human and animal biospecimens for research and clinical applications. Since its founding in 1999, the company has built a reputation for quality and reliability in supplying cell-based materials to pharmaceutical, biotech and academic institutions. Headquartered in Van Nuys, California, HemaCare serves as a critical link in the development of new therapies and diagnostic tools.
The company’s core offerings include the collection and isolation of peripheral blood mononuclear cells (PBMCs), granulocytes, monocytes and other white blood cell subtypes. In addition to traditional blood components, HemaCare provides access to bone marrow aspirates, cord blood mononuclear cells and leukapheresis products. All specimens are processed under stringent quality standards and can be tailored to meet Good Manufacturing Practices (GMP) requirements for clinical and translational research.
Through an integrated network of collection sites and partner clinics, HemaCare supports customers across North America, Europe and Asia. The company’s logistics and sample management systems ensure traceability, cold-chain integrity and on-time delivery to research laboratories and contract research organizations. HemaCare’s global reach allows it to cater to diverse therapeutic areas, including immuno-oncology, cell and gene therapy, transplant biology and vaccine development.
HemaCare is led by an experienced management team headed by President and CEO David W. Oliver, whose background spans over 20 years in cell therapy manufacturing and bioprocessing. The leadership team also includes Chief Scientific Officer Dr. Susan Lee and Chief Financial Officer Maria Hernandez, who together guide strategic growth initiatives and ongoing product innovation.
AI Generated. May Contain Errors.
